The identification of a potent inhibitor against YAP/TAZ, K-975, has already shown increased lifespan in malignant pleural mesothelioma xenograft mice, suggesting that YAP/TAZ targeting could provide another considerable therapeutic option (Kaneda et al., 2020). Here, TAFAZZIN is linked to malignant pleural mesothelioma.